Clinical trials: Thrombotic Microangiopathies
Purpura, Thrombotic Thrombocytopenic, Hemolytic Uremic Syndrome
The Plasma Large-Volume Exchange RCT
Thrombotic thrombocytopenia purpura / hemolytic uremic syndrome (TTP/HUS) is a rare, life-threatening disorder. TTP/HUS causes multiple blood clots to form, which prevents blood from reaching the brain and kidneys.
- Trial name
- PLEX-RCT (NCT01433003)
- Testing
- Plasma Exchange
- Where
- Canada
- Sponsor
- London Health Sciences Centre
Immune Thrombocytopenic Purpura
Helicobacter Pylori Immune Thrombocytopenic Purpura
We designed a study for evaluate the efficacy of Helicobacter pylori eradication for the 1st line treatment of immune thrombocytopenic purpura (ITP) patients with moderate thrombocytopenia.
- Trial name
- HpyloriITP (NCT01255332)
- Where
- South Korea
- Volunteers
- 26 people
- Sponsor
- Cooperative Study Group A for Hematology
Immune Thrombocytopenia
Combined Steroid and Cyclosporin as First-line Treatment in Adults With Primary Immune Thrombocytopenia
Randomized, open-label, multicenter study to compare the efficacy and safety of cyclosporin plus standard steroid compared to standard steroid monotherapy for the first-line treatment of adults with primary immune…
- Trial name
- NCT05459649
- Testing
- Cyclosporine Oral Product, Prednisone
- Where
- China
- Volunteers
- 253 people
- Sponsor
- Peking University People's Hospital
Primary Immune Thrombocytopenia
A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia
The study is designed to be a randomized, open, multi-center, phase IIa/IIb seamless adaptive trial. Phase IIa: The study consists of a screening period, a core treatment period, an open label extension period, and a safety…
- Trial name
- NCT05232149
- Testing
- Orelabrutinib( lower dose), Orelabrutinib( higher dose)
- Where
- 9 sites in China
- Volunteers
- 30 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
Systemic Lupus Erythematosus
Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus
This study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy of KP104 in participants with systemic lupus erythematosus (SLE)-Thrombotic microangiopathy (TMA).
- Trial name
- NCT05504187
- Testing
- KP104
- Volunteers
- 24 people
- Sponsor
- Kira Pharmacenticals (US), LLC.
Atypical Hemolytic Uremic Syndrome, Pregnancy
Eculizumab Use in the Postpartum Period for the Treatment of Pregnancy Associated aHUS: A Case Series
Eculizumab is a humanized monoclonal IgG antibody against protein C5 that works to inhibit the activation of the terminal complement cascade.
- Trial name
- NCT03574506
- Where
- Colombia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Fundación Grupo de Investigación en Cuidados Intensivos y Obstetricia
Immune Thrombocytopenic Purpura
Eltrombopag and High-dose Dexamethasone as First Line Treatment for IT
The purpose of this study is to determine the response rate and response duration with the combination of eltrombopag and high-dose dexamethasone
- Trial name
- NCT01652599
- Testing
- Eltrombopag and dexamethasone
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Hospital Universitario Dr. Jose E. Gonzalez
Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy
Thymoglobulin® Pharmacokinetics in Patients Undergoing Hematopoietic Stem Cell Transplantation
Thymoglobulin is widely applied as serotherapy in order to prevent acute graft-versus-host disease (GvHD) and graft rejection in patients undergoing non-Human Leukocyte Antigen (HLA)-identical hematopoietic stem cell…
- Trial name
- PHASAL-GA (NCT05743400)
- Testing
- Thymoglobulin 25 milligrams (mg) Injection, blood test
- Where
- 2 sites in France
- Volunteers
- 35 people
- Sponsor
- Hospices Civils de Lyon
Immune Thrombocytopenic Purpura, Helicobacter Pylori Infection
Helicobacter Pylori Treatment in Immune Thrombocytopenic Purpura (ITP) Patients
The purpose of this study is to determine whether eradication of Helicobacter pylori infection is effective in the improvement of platelet counts in children and adolescents with chronic ITP.
- Trial name
- NCT01730352
- Testing
- H. pylori triple therapy
- Where
- 4 sites in Brazil
- Volunteers
- 100 people
- Sponsor
- Federal University of São Paulo
Idiopathic Thrombocytopenic Purpura
A Study in Healthy Subjects to Evaluate Bioavailability of 4 Formulations of E5501
This is a study in healthy subjects. There are two parts to the study. In the first part of the study each subject will receive a single 10mg dose of each of the four formulations of E550.
- Trial name
- NCT01549054
- Testing
- 10-mg dose of E5501 2G tablet, 10-mg dose of E5501 cyclodextrin oral solution, 10-mg dose of E5501-P21% powder
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Thrombocytopenic Purpura
Lymphocyte Counts in Immune Thrombocytopenic Purpura
immune thrombocytopenic purpura is an acquired autoimmune disorder characterized by increased platelet destruction and decreased platelet number (cooper N et al 2006) recent studies have demonstrated that the pathogenesis of ITP…
- Trial name
- NCT03244410
- Testing
- complete blood picture
- Volunteers
- 1 people
- Sponsor
- Assiut University
Immune Thrombocytopenic Purpura
Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults
Octagam is a solvent/detergent-treated human normal immunoglobulin (IGIV) solution for intravenous administration. Octagam 5% is currently registered in about 80 countries.
- Trial name
- NCT00426270
- Testing
- Octagam 10%
- Where
- Austria
- Volunteers
- 116 people
- Sponsor
- Octapharma
Atypical Hemolytic Uremic Syndrome (aHUS)
A Retrospective, Observational, Non-interventional Trial to Assess Eculizumab Treatment Effect in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
The objective of this retrospective trial is to assess safety and efficacy of eculizumab in aHUS patients treated outside of an Alexion-sponsored controlled clinical trial.
- Trial name
- NCT01770951
- Where
- 23 sites in United States, Austria and 6 more
- Volunteers
- 30 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia
A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)
The main purpose of this study is to confirm the correct dose of efgartigimod IV for treating patients aged 12 to younger than 18 years with chronic immune thrombocytopenia (ITP).
- Conditions
- Immune Thrombocytopenia (ITP), ITP - Immune Thrombocytopenia, ITP, Immune Thrombocytopenic Purpura
- Trial name
- Advance Jr (NCT07194850)
- Testing
- Efgartigimod IV
- Where
- 26 sites in France, Germany and 8 more
- Volunteers
- 24 people
- Sponsor
- argenx
Acquired Thrombotic Thrombocytopenic Purpura
Follow-up Study for Patients Who Completed Study ALX0681-C301 (Post-HERCULES)
The objectives of this study were to evaluate long-term safety and efficacy of caplacizumab, to evaluate safety and efficacy of repeated use of caplacizumab and to characterize long-term impact of acquired thrombotic…
- Trial name
- NCT02878603
- Testing
- Caplacizumab, Standard of Care
- Where
- 45 sites in United States, Austria and 11 more
- Volunteers
- 104 people
- Sponsor
- Sanofi
Immune Thrombocytopenia
Open-Label Study to Evaluate the Safety and Efficacy of Avatrombopag and Remission Rates in Adults With ITP of ≤6 Months
This study will evaluate the safety and efficacy of avatrombopag in subjects with a confirmed diagnosis of primary ITP (≤6 months duration) over 26 weeks of treatment, and also evaluate the incidence of ITP remission.
- Trial name
- NCT05046327
- Testing
- Avatrombopag 20 mg Oral Tablet
- Sponsor
- Sobi, Inc.
Relapsed/Refractory Immune Thrombocytopenia
The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia
to investigate efficacy and safety evaluation of bortezomib in patients with relapsed/refractory immune thrombocytopenia
- Trial name
- NCT05599880
- Testing
- Bortezomib
- Where
- 4 sites in South Korea
- Volunteers
- 29 people
- Sponsor
- Seoul National University Hospital
Immune Thrombocytopenia
Different Cycles of High-dose Dexamethasone for Initial Management of Primary Immune Thrombocytopenia (ITP)
The project was organized by Qilu Hospital of Shandong University in China. In order to report the efficacy and safety of different cycles of high-dose dexamethasone for the treatment of adults with newly-diagnosed primary immune…
- Trial name
- NCT02642380
- Testing
- Dexamethasone (4 cycles), Dexamethasone (1 cycle)
- Where
- China
- Sponsor
- Shandong University
Immune Thrombocytopenia
DEX Combined With RTX, CSA and IVIG in the Management of Newly Diagnosed ITP Patients
The project was undertaken by Qilu Hospital, Shandong University in China. In order to report the efficacy and safety of dexamethasone combined with rituximab, cyclosporin and intravenous immunoglobulin in the management of newly…
- Trial name
- NCT02834468
- Testing
- DEX Combined With RTX, CSA and IVIG
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Shandong University
Primary Immune Thrombocytopenia
Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study
Description of the use of fostamatinib in patients with PTI in the Andalusian region.
- Trial name
- NCT06071520
- Testing
- Fostamatinib
- Where
- 14 sites in Spain
- Volunteers
- 50 people
- Sponsor
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla